BioSpace News Archive

Promore Pharma AB announced that the company has entered into voluntary liquidation and that the Swedish Companies Registration Office has appointed attorney Lars-Henrik Andersson as liquidator.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET.

PROCEPT BioRobotics® Corporation, a surgical robotics global leader, is pleased to announce that the National Institute for Health and Care Excellence has bestowed its strongest endorsement, the “standard arrangements” recommendation, on Aquablation® therapy for the treatment of benign prostatic hyperplasia.

ProPhase Labs, Inc. today announced it will be participating in The ThinkEquity Conference, which will take place on October 19, 2023 at The Mandarin Oriental Hotel in New York.

Longeveron Inc. today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock.

Akeso, Inc. (9926.HK) (“Akeso”) announced that the results of the multicenter, open-label Phase Ib/II clinical trial (COMPASSION-03/AK104-201) for cadonilimab (PD-1/CTLA-4 bispecific antibody), the globally first bispecific IO drug used to treat advanced solid tumors, have been published in the October 2 issue of The Lancet Oncology.

InMode Ltd., a leading global provider of innovative medical technologies, announced that it expects to release its financial results for the third quarter of 2023 before the Nasdaq market opens on Thursday, Nov. 2, 2023.

Sun Scientific, an innovative provider of compression and wound care solutions, is pleased to announce the appointment of Jeff Schultz as the new Vice President of Sales, North America.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the addition of two denosumab biosimilars referencing both Prolia ® and XGEVA ® to its biosimilar pipeline.